<DOC>
	<DOCNO>NCT01003093</DOCNO>
	<brief_summary>The purpose study evaluate safety profile adjuvanted TB subunit vaccine administer 0 2 month healthy BCG-unvaccinated volunteer prior history TB disease know prior exposure TB</brief_summary>
	<brief_title>A Safety Immunogenicity Trial With Adjuvanted Tuberculosis ( TB ) Subunit Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male Healthy base medical examination/history inclusion Age 18 55 year Signed informed consent Prepared grant authorize person access medical record The volunteer likely comply instruction Known exposure TB ( expect ) trial Prior BCG vaccination Granulomatous disease ( chest Xray , autoimmune screen ) Vaccinated live vaccine 3 month first vaccination Administration immune modulate drug ( steroid , immunosuppressive drug immunoglobulin ) 3 month first vaccination HBV , HCV HIV seropositive ( HBsAg , HBsAb , HBc total IgM ab HCV , HIV1 HIV2 ab ) Participation clinical trial Positive Mantoux QuantiFERONTB Gold Known hypersensitivity vaccine component Laboratory parameter outside normal range consider clinically relevant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Ag85B</keyword>
	<keyword>ESAT-6</keyword>
	<keyword>IC31</keyword>
</DOC>